Evidence map›Paper›PMID 39974928›Full record

ArticlebioRxiv : the preprint server for biology2025

The SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity.

Kristen C Witt, Adam Dziulko, Joohyun An, Filip Pekovic, Arthur Xiuyuan Cheng, Grace Y Liu, Ophelia Vosshall Lee, David J Turner, Azra Lari, Moritz M Gaidt and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Kristen C WittHoward Hughes Medical Institute, University of California, Berkeley, CA, USA.ORCID 0000-0001-8744-9457
Adam DziulkoDepartment of Molecular, Cellular, and Developmental Biology and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
Joohyun AnDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Filip PekovicNational Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Arthur Xiuyuan ChengDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Grace Y LiuHoward Hughes Medical Institute, University of California, Berkeley, CA, USA.
Ophelia Vosshall LeeDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
David J TurnerNational Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Azra LariDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA.
Moritz M GaidtDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Roberto ChavezHoward Hughes Medical Institute, University of California, Berkeley, CA, USA.
Stefan A FattingerDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Preethy AbrahamDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Harmandeep DhaliwalCancer Research Laboratory, University of California, Berkeley, CA, USA.
Angus Y LeeCancer Research Laboratory, University of California, Berkeley, CA, USA.
Dmitri I KotovDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.ORCID 0000-0001-7843-1503
Laurent CoscoyDivision of Immunology and Molecular Medicine, University of California, Berkeley, CA, USA.
Britt A GlaunsingerHoward Hughes Medical Institute, University of California, Berkeley, CA, USA.
Eugene ValkovNational Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0002-3721-1739
Edward B ChuongDepartment of Molecular, Cellular, and Developmental Biology and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.ORCID 0000-0002-5392-937X
Russell E VanceHoward Hughes Medical Institute, University of California, Berkeley, CA, USA.ORCID 0000-0002-6686-3912

Funding

The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI STANLEY, SARAH A · 2004 to 2025
$45.5M
Functional and Structural Dissection of Inflammasome ActivationR37AI075039 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI RUSSELL E VANCE · 2018 to 2026
$3.8M
Specificity and in vivo function of the Naip/Nlrc4 inflammasomesR01AI075039 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI VANCE, RUSSELL E · 2008 to 2017
$3.6M
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse modelR01AI155634 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI VANCE, RUSSELL E · 2020 to 2024
$2.2M
NIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI075039NIAID NIH HHS R01 AI155634NIAID NIH HHS R37 AI075039
6 · The paper itself

Abstract

Type I interferons (IFN-Is) are essential for antiviral immunity but must be tightly regulated

Identifiers

PMID39974928
PMCPMC11838211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.